Last update Aug. 29, 2022

C6512H10066N1730O2052S46

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps associated with chronic rhinosinusitis. Subcutaneous administration every 2 weeks.

Since the last update we have not found published data on its excretion in breastmilk.

It´s very high molecular weight (> 100,000 Da) makes it very unlikely to pass into breast milk in a significant quantity.

Due to its protein nature, it is inactivated in the gastrointestinal tract without being absorbed (practically nil oral bioavailability) and this hinders or prevents its passage into the infant´s plasma from ingested breast milk, except for premature infants and during the immediate neonatal period when there might be a greater intestinal permeability.

No problems have been seen in an infant whose mother was treated with dupilumab. (Kage 2021 and 2020)

 

Alternatives

We do not have alternatives for C6512H10066N1730O2052S46.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C6512H10066N1730O2052S46 is Dupilumab in Molecular formula.

Is written in other languages:

Groups

C6512H10066N1730O2052S46 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C6512H10066N1730O2052S46 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 146.897 daltons
VD 0.07 l/Kg
Tmax 72 - 168 hours
T½ > 240 hours

References

  1. Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207 Full text (link to original source) Full text (in our servers)
  2. Kage P, Simon JC, Treudler R. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. J Dermatol. 2021 Oct;48(10):E484-E485. Abstract
  3. Treudler R, Kage P, Simon JC. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. Allergy. 2020;75 Suppl. 109:432. Abstract 0071. Abstract Full text (link to original source) Full text (in our servers)
  4. EMA. Dupilumab. Ficha técnica. 2017 Full text (in our servers)
  5. Sanofi. Dupilumab. Drug Summary. 2017 Full text (in our servers)

Total visits

533

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM